Global Influenza Vaccines research
Global Influenza Vaccines research

Influenza Vaccines Comprehensive Study by Type (Paediatrics, Adolescence, Adults, Elderly), Application (Hospitals, Clinics, Others), Technology (Egg Based, Cell Culture, Recombinant), Vaccines (Fluzone, Flumist, Fluvirin, Fluvax) Players and Region - Global Market Outlook to 2024

Influenza Vaccines Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

May 2019 Edition 242 Pages 168 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Influenza Vaccines Market Overview:
Influenza Vaccines is also known as flu shot that applicable for protection against influenza vaccine. The influenza vaccine consist of three influenza viruses such as influenza type A with H3N2 virus strain, influenza type A with H1N1 virus strain and influenza type B virus strain. The major companies are introducing latest vaccination that beneficial in providing Over-the Counter products that are likely to create oppurtunities for generic manufacturers.Further, increasing demand from the developing countries owing to growth in the vaccination owing to increasing application in various clinic, hospitals and others.

Market Drivers
  • Increasing Awareness About the Pandemic Influenza Viruses Propelled the Market.
  • Rising Government Initiatives for Vaccines against Influenza Fuelled up the Market.

Market Trend
  • Collaboration and Tie Up Of Leading Players
  • Value Oriented Consumers

Restraints
  • Strict Regulation Associated With New Entrant of this Market.
  • High Amount Of Investments Required For Influenza Vaccines Market.

Opportunities
  • Popularity Of Quadrivalent Vaccines is Expected To Boost The Influenza Vaccines Market.
  • Rapid Demand of Influenza Vaccines in North America Regions Leads to Propel the Market.

Challenges
  • Complexity Involved In Development and Approval System of Influenza Vaccines Market.


Competitive Landscape:

Some of the key players profiled in the report are Abbott (United States),, AstraZeneca (United Kingdom), BioCryst Pharmaceuticals, Inc. (United States),, Novartis AG (United States),, DAIICHI SANKYO COMPANY, LIMITED. (Japan), GlaxoSmithKline plc. (United Kingdom), Hualan Biological Engineering Inc (China), Mitsubishi Tanabe Pharma Corporation (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Novavax (United States) and BioCryst (United States). Additionally, following companies can also be profiled that are part of our coverage like Sanofi (France), Seqirus Vaccines Limited (United Kingdom), FluGen (United States) and Moderna Therapeutics (United States). Analyst at AdvanceMarketAnalytics see United States and United Kingdom Players to retain maximum share of Global Influenza Vaccines market by 2024. Considering Market by Technology, the sub-segment i.e. Egg Based will boost the Influenza Vaccines market. Considering Market by Vaccines, the sub-segment i.e. Fluzone will boost the Influenza Vaccines market.

Market Highlights:

In April 2019, Seqirus launched an advanced in Cell based influenza vaccine technology which is beneficial in providing prevention and pandemic preparedness. The product expansion is beneficial in fulfilling its demand in U.S. and European regions.

“According to US Food and Drug Administration (FDA) approved the first quadrivalent influenza vaccine, an inhaled live attenuated influenza vaccine developed by MedImmune and modeled after its FluMist product. ”

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Influenza Vaccines market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Influenza Vaccines market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Influenza Vaccines Manufacturers, Influenza Vaccines Traders, End-Use Market Participants of Different Segments of Influenza Vaccines, Government and Research Organizations, R&D Institutions and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Paediatrics
  • Adolescence
  • Adults
  • Elderly
By Application
  • Hospitals
  • Clinics
  • Others
By Technology
  • Egg Based
  • Cell Culture
  • Recombinant

By Vaccines
  • Fluzone
  • Flumist
  • Fluvirin
  • Fluvax

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Awareness About the Pandemic Influenza Viruses Propelled the Market.
      • 3.2.2. Rising Government Initiatives for Vaccines against Influenza Fuelled up the Market.
    • 3.3. Market Challenges
      • 3.3.1. Complexity Involved In Development and Approval System of Influenza Vaccines Market.
    • 3.4. Market Trends
      • 3.4.1. Collaboration and Tie Up Of Leading Players
      • 3.4.2. Value Oriented Consumers
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Influenza Vaccines, by Type, Application, Technology, Vaccines and Region (value and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Influenza Vaccines (Value)
      • 5.2.1. Global Influenza Vaccines by: Type (Value)
        • 5.2.1.1. Paediatrics
        • 5.2.1.2. Adolescence
        • 5.2.1.3. Adults
        • 5.2.1.4. Elderly
      • 5.2.2. Global Influenza Vaccines by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Influenza Vaccines by: Technology (Value)
        • 5.2.3.1. Egg Based
        • 5.2.3.2. Cell Culture
        • 5.2.3.3. Recombinant
      • 5.2.4. Global Influenza Vaccines by: Vaccines (Value)
        • 5.2.4.1. Fluzone
        • 5.2.4.2. Flumist
        • 5.2.4.3. Fluvirin
        • 5.2.4.4. Fluvax
      • 5.2.5. Global Influenza Vaccines Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Influenza Vaccines (Price)
      • 5.3.1. Global Influenza Vaccines by: Type (Price)
  • 6. Influenza Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott (United States),
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BioCryst Pharmaceuticals, Inc. (United States),
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis AG (United States),
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. DAIICHI SANKYO COMPANY, LIMITED. (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Hualan Biological Engineering Inc (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mitsubishi Tanabe Pharma Corporation (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novavax (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. BioCryst (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Influenza Vaccines Sale, by Type, Application, Technology, Vaccines and Region (value and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Influenza Vaccines (Value)
      • 7.2.1. Global Influenza Vaccines by: Type (Value)
        • 7.2.1.1. Paediatrics
        • 7.2.1.2. Adolescence
        • 7.2.1.3. Adults
        • 7.2.1.4. Elderly
      • 7.2.2. Global Influenza Vaccines by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Influenza Vaccines by: Technology (Value)
        • 7.2.3.1. Egg Based
        • 7.2.3.2. Cell Culture
        • 7.2.3.3. Recombinant
      • 7.2.4. Global Influenza Vaccines by: Vaccines (Value)
        • 7.2.4.1. Fluzone
        • 7.2.4.2. Flumist
        • 7.2.4.3. Fluvirin
        • 7.2.4.4. Fluvax
      • 7.2.5. Global Influenza Vaccines Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Influenza Vaccines (Price)
      • 7.3.1. Global Influenza Vaccines by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Influenza Vaccines: by Type(USD Million)
  • Table 2. Influenza Vaccines Paediatrics , by Region USD Million (2013-2018)
  • Table 3. Influenza Vaccines Adolescence , by Region USD Million (2013-2018)
  • Table 4. Influenza Vaccines Adults , by Region USD Million (2013-2018)
  • Table 5. Influenza Vaccines Elderly , by Region USD Million (2013-2018)
  • Table 6. Influenza Vaccines: by Application(USD Million)
  • Table 7. Influenza Vaccines Hospitals , by Region USD Million (2013-2018)
  • Table 8. Influenza Vaccines Clinics , by Region USD Million (2013-2018)
  • Table 9. Influenza Vaccines Others , by Region USD Million (2013-2018)
  • Table 10. Influenza Vaccines: by Technology(USD Million)
  • Table 11. Influenza Vaccines Egg Based , by Region USD Million (2013-2018)
  • Table 12. Influenza Vaccines Cell Culture , by Region USD Million (2013-2018)
  • Table 13. Influenza Vaccines Recombinant , by Region USD Million (2013-2018)
  • Table 14. Influenza Vaccines: by Vaccines(USD Million)
  • Table 15. Influenza Vaccines Fluzone , by Region USD Million (2013-2018)
  • Table 16. Influenza Vaccines Flumist , by Region USD Million (2013-2018)
  • Table 17. Influenza Vaccines Fluvirin , by Region USD Million (2013-2018)
  • Table 18. Influenza Vaccines Fluvax , by Region USD Million (2013-2018)
  • Table 19. South America Influenza Vaccines, by Country USD Million (2013-2018)
  • Table 20. South America Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 21. South America Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 22. South America Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 23. South America Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 24. Brazil Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 25. Brazil Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 26. Brazil Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 27. Brazil Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 28. Argentina Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 29. Argentina Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 30. Argentina Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 31. Argentina Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 32. Rest of South America Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 33. Rest of South America Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 34. Rest of South America Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 35. Rest of South America Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 36. Asia Pacific Influenza Vaccines, by Country USD Million (2013-2018)
  • Table 37. Asia Pacific Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 38. Asia Pacific Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 39. Asia Pacific Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 40. Asia Pacific Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 41. China Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 42. China Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 43. China Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 44. China Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 45. Japan Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 46. Japan Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 47. Japan Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 48. Japan Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 49. India Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 50. India Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 51. India Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 52. India Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 53. South Korea Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 54. South Korea Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 55. South Korea Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 56. South Korea Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 57. Taiwan Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 58. Taiwan Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 59. Taiwan Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 60. Taiwan Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 61. Australia Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 62. Australia Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 63. Australia Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 64. Australia Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 65. Rest of Asia-Pacific Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 66. Rest of Asia-Pacific Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 67. Rest of Asia-Pacific Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 68. Rest of Asia-Pacific Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 69. Europe Influenza Vaccines, by Country USD Million (2013-2018)
  • Table 70. Europe Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 71. Europe Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 72. Europe Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 73. Europe Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 74. Germany Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 75. Germany Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 76. Germany Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 77. Germany Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 78. France Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 79. France Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 80. France Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 81. France Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 82. Italy Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 83. Italy Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 84. Italy Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 85. Italy Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 86. United Kingdom Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 87. United Kingdom Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 88. United Kingdom Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 89. United Kingdom Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 90. Netherlands Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 91. Netherlands Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 92. Netherlands Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 93. Netherlands Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 94. Rest of Europe Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 95. Rest of Europe Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 96. Rest of Europe Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 97. Rest of Europe Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 98. MEA Influenza Vaccines, by Country USD Million (2013-2018)
  • Table 99. MEA Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 100. MEA Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 101. MEA Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 102. MEA Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 103. Middle East Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 104. Middle East Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 105. Middle East Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 106. Middle East Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 107. Africa Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 108. Africa Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 109. Africa Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 110. Africa Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 111. North America Influenza Vaccines, by Country USD Million (2013-2018)
  • Table 112. North America Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 113. North America Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 114. North America Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 115. North America Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 116. United States Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 117. United States Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 118. United States Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 119. United States Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 120. Canada Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 121. Canada Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 122. Canada Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 123. Canada Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 124. Mexico Influenza Vaccines, by Type USD Million (2013-2018)
  • Table 125. Mexico Influenza Vaccines, by Application USD Million (2013-2018)
  • Table 126. Mexico Influenza Vaccines, by Technology USD Million (2013-2018)
  • Table 127. Mexico Influenza Vaccines, by Vaccines USD Million (2013-2018)
  • Table 128. Influenza Vaccines: by Type(USD/Units)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Influenza Vaccines: by Type(USD Million)
  • Table 141. Influenza Vaccines Paediatrics , by Region USD Million (2019-2024)
  • Table 142. Influenza Vaccines Adolescence , by Region USD Million (2019-2024)
  • Table 143. Influenza Vaccines Adults , by Region USD Million (2019-2024)
  • Table 144. Influenza Vaccines Elderly , by Region USD Million (2019-2024)
  • Table 145. Influenza Vaccines: by Application(USD Million)
  • Table 146. Influenza Vaccines Hospitals , by Region USD Million (2019-2024)
  • Table 147. Influenza Vaccines Clinics , by Region USD Million (2019-2024)
  • Table 148. Influenza Vaccines Others , by Region USD Million (2019-2024)
  • Table 149. Influenza Vaccines: by Technology(USD Million)
  • Table 150. Influenza Vaccines Egg Based , by Region USD Million (2019-2024)
  • Table 151. Influenza Vaccines Cell Culture , by Region USD Million (2019-2024)
  • Table 152. Influenza Vaccines Recombinant , by Region USD Million (2019-2024)
  • Table 153. Influenza Vaccines: by Vaccines(USD Million)
  • Table 154. Influenza Vaccines Fluzone , by Region USD Million (2019-2024)
  • Table 155. Influenza Vaccines Flumist , by Region USD Million (2019-2024)
  • Table 156. Influenza Vaccines Fluvirin , by Region USD Million (2019-2024)
  • Table 157. Influenza Vaccines Fluvax , by Region USD Million (2019-2024)
  • Table 158. South America Influenza Vaccines, by Country USD Million (2019-2024)
  • Table 159. South America Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 160. South America Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 161. South America Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 162. South America Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 163. Brazil Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 164. Brazil Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 165. Brazil Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 166. Brazil Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 167. Argentina Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 168. Argentina Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 169. Argentina Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 170. Argentina Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 171. Rest of South America Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 172. Rest of South America Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 173. Rest of South America Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 174. Rest of South America Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 175. Asia Pacific Influenza Vaccines, by Country USD Million (2019-2024)
  • Table 176. Asia Pacific Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 177. Asia Pacific Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 178. Asia Pacific Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 179. Asia Pacific Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 180. China Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 181. China Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 182. China Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 183. China Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 184. Japan Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 185. Japan Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 186. Japan Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 187. Japan Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 188. India Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 189. India Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 190. India Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 191. India Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 192. South Korea Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 193. South Korea Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 194. South Korea Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 195. South Korea Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 196. Taiwan Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 197. Taiwan Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 198. Taiwan Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 199. Taiwan Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 200. Australia Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 201. Australia Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 202. Australia Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 203. Australia Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 204. Rest of Asia-Pacific Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 205. Rest of Asia-Pacific Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 206. Rest of Asia-Pacific Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 207. Rest of Asia-Pacific Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 208. Europe Influenza Vaccines, by Country USD Million (2019-2024)
  • Table 209. Europe Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 210. Europe Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 211. Europe Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 212. Europe Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 213. Germany Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 214. Germany Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 215. Germany Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 216. Germany Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 217. France Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 218. France Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 219. France Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 220. France Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 221. Italy Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 222. Italy Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 223. Italy Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 224. Italy Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 225. United Kingdom Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 226. United Kingdom Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 227. United Kingdom Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 228. United Kingdom Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 229. Netherlands Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 230. Netherlands Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 231. Netherlands Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 232. Netherlands Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 233. Rest of Europe Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 234. Rest of Europe Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 235. Rest of Europe Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 236. Rest of Europe Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 237. MEA Influenza Vaccines, by Country USD Million (2019-2024)
  • Table 238. MEA Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 239. MEA Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 240. MEA Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 241. MEA Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 242. Middle East Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 243. Middle East Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 244. Middle East Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 245. Middle East Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 246. Africa Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 247. Africa Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 248. Africa Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 249. Africa Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 250. North America Influenza Vaccines, by Country USD Million (2019-2024)
  • Table 251. North America Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 252. North America Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 253. North America Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 254. North America Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 255. United States Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 256. United States Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 257. United States Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 258. United States Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 259. Canada Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 260. Canada Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 261. Canada Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 262. Canada Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 263. Mexico Influenza Vaccines, by Type USD Million (2019-2024)
  • Table 264. Mexico Influenza Vaccines, by Application USD Million (2019-2024)
  • Table 265. Mexico Influenza Vaccines, by Technology USD Million (2019-2024)
  • Table 266. Mexico Influenza Vaccines, by Vaccines USD Million (2019-2024)
  • Table 267. Influenza Vaccines: by Type(USD/Units)
  • Table 268. Research Programs/Design for This Report
  • Table 269. Key Data Information from Secondary Sources
  • Table 270. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Influenza Vaccines: by Type USD Million (2013-2018)
  • Figure 5. Global Influenza Vaccines: by Application USD Million (2013-2018)
  • Figure 6. Global Influenza Vaccines: by Technology USD Million (2013-2018)
  • Figure 7. Global Influenza Vaccines: by Vaccines USD Million (2013-2018)
  • Figure 8. South America Influenza Vaccines Share (%), by Country
  • Figure 9. Asia Pacific Influenza Vaccines Share (%), by Country
  • Figure 10. Europe Influenza Vaccines Share (%), by Country
  • Figure 11. MEA Influenza Vaccines Share (%), by Country
  • Figure 12. North America Influenza Vaccines Share (%), by Country
  • Figure 13. Global Influenza Vaccines: by Type USD/Units (2013-2018)
  • Figure 14. Global Influenza Vaccines share by Players 2018 (%)
  • Figure 15. Global Influenza Vaccines share by Players (Top 3) 2018(%)
  • Figure 16. Global Influenza Vaccines share by Players (Top 5) 2018(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Abbott (United States), Revenue, Net Income and Gross profit
  • Figure 19. Abbott (United States), Revenue: by Geography 2018
  • Figure 20. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. AstraZeneca (United Kingdom) Revenue: by Geography 2018
  • Figure 22. BioCryst Pharmaceuticals, Inc. (United States), Revenue, Net Income and Gross profit
  • Figure 23. BioCryst Pharmaceuticals, Inc. (United States), Revenue: by Geography 2018
  • Figure 24. Novartis AG (United States), Revenue, Net Income and Gross profit
  • Figure 25. Novartis AG (United States), Revenue: by Geography 2018
  • Figure 26. DAIICHI SANKYO COMPANY, LIMITED. (Japan) Revenue, Net Income and Gross profit
  • Figure 27. DAIICHI SANKYO COMPANY, LIMITED. (Japan) Revenue: by Geography 2018
  • Figure 28. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2018
  • Figure 30. Hualan Biological Engineering Inc (China) Revenue, Net Income and Gross profit
  • Figure 31. Hualan Biological Engineering Inc (China) Revenue: by Geography 2018
  • Figure 32. Mitsubishi Tanabe Pharma Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 33. Mitsubishi Tanabe Pharma Corporation (Japan) Revenue: by Geography 2018
  • Figure 34. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2018
  • Figure 36. Novavax (United States) Revenue, Net Income and Gross profit
  • Figure 37. Novavax (United States) Revenue: by Geography 2018
  • Figure 38. BioCryst (United States) Revenue, Net Income and Gross profit
  • Figure 39. BioCryst (United States) Revenue: by Geography 2018
  • Figure 40. Global Influenza Vaccines: by Type USD Million (2019-2024)
  • Figure 41. Global Influenza Vaccines: by Application USD Million (2019-2024)
  • Figure 42. Global Influenza Vaccines: by Technology USD Million (2019-2024)
  • Figure 43. Global Influenza Vaccines: by Vaccines USD Million (2019-2024)
  • Figure 44. South America Influenza Vaccines Share (%), by Country
  • Figure 45. Asia Pacific Influenza Vaccines Share (%), by Country
  • Figure 46. Europe Influenza Vaccines Share (%), by Country
  • Figure 47. MEA Influenza Vaccines Share (%), by Country
  • Figure 48. North America Influenza Vaccines Share (%), by Country
  • Figure 49. Global Influenza Vaccines: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Abbott (United States),
  • AstraZeneca (United Kingdom)
  • BioCryst Pharmaceuticals, Inc. (United States),
  • Novartis AG (United States),
  • DAIICHI SANKYO COMPANY, LIMITED. (Japan)
  • GlaxoSmithKline plc. (United Kingdom)
  • Hualan Biological Engineering Inc (China)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Novavax (United States)
  • BioCryst (United States)
Additional players considered in the study are as follows:
Sanofi (France) , Seqirus Vaccines Limited (United Kingdom) , FluGen (United States) , Moderna Therapeutics (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation